权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical and experimental studies on lymph node metastasis in lung cancer

肺癌淋巴结转移的临床与实验研究

基本信息

批准号：
05454382
负责人：
WATANABE Yoh
金额：
$ 4.35万
依托单位：
Kanazawa University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05454382/
关键词：
Primary lung cancer Lymphnode metastasis Matrix metalloproteinase Sinus histiocytosis PCNA Apoptosis Prognostic factor Model of advanced lung cancer 肺癌リンパ節転移モデル sinus histiocytosis 自己腫瘍細胞傷害活性核DNA量マトリックスメタロプロテナーゼ

项目摘要

1.Cox's multivariate analysis clarified that DNA ploidy and tumor size were significant prognostic factors of stage-1 lung cancer. DNA aneuploid tumors might have lymphnode micrometastasis and subclinical distant metastasis.2.There was no relationship between the degree of sinus histiocytosis (SH) and follicular hyperplasia (FH) of metastatic lymph nodes, and histological types. But the high SH adenocarcinomas and the high FH squamous cell carcinomas showed favorable prognosis.3.The activated matrix-metalloproteinase (MMP-2) was found specifically in cancer tissue. And its activity in the tumors with lymph node involvement was significantly higher than nodenegative ones. Membranous-type MMP was over-expressed in the tumor tissue, and there was relationship between the activity of MMP2 and the expression of MT-MMP.4.The frequency of lymphnode metastasis correlated positively with tumor size but not with PCNA labeling index (LI) %. There was no lymphnode metastasis when the tumor was less than 30mm in diameter and the PCNA LI% was high. Difference of PCNA LI% were detected even in the same DNA ploidy pattern. The double staining technique of PCNA and DNA contents with FCM provided useful biological parameters in evaluating the malignant potential of lung cancer.5.Experimental study of therapy of advanced lung cancer by M109 mouse model showed that preoperative systemic chemo-and radiation therapy was effective to reduce the number of metastatic lesions to lymphnodes and lungs.

1.Cox多因素分析表明，DNA倍体和肿瘤大小是影响Ⅰ期肺癌预后的重要因素。DNA异倍体肿瘤可能存在淋巴结微转移和亚临床远处转移。2.转移淋巴结的窦组织细胞增生（SH）和滤泡增生（FH）程度与组织学类型无关。而高SH腺癌和高FH鳞癌则表现出较好的浸润性。3. MMP-2在癌组织中特异性表达。有淋巴结转移的肿瘤中其活性明显高于无淋巴结转移的肿瘤。4.淋巴结转移率与肿瘤大小呈正相关，而与PCNA标记指数（LI）%无关。肿瘤直径小于30 mm，PCNA LI%高，无淋巴结转移。同一DNA倍体的PCNA LI%也有差异。流式细胞术检测PCNA和DNA含量的双染技术为评价肺癌的恶性潜能提供了有用的生物学参数。5. M109小鼠晚期肺癌治疗的实验研究表明，术前全身化疗和放疗能有效减少淋巴结和肺转移灶的数目。